# High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed

> **NCT06972602** · EARLY_PHASE1 · RECRUITING · sponsor: **Eye & ENT Hospital of Fudan University** · enrollment: 10 (estimated)

## Conditions studied

- Retinoblastoma
- Retinoblastoma, Recurrent

## Interventions

- **DRUG:** Topotecan
- **OTHER:** Collection of aqueous humor
- **OTHER:** Electroretinogram

## Key facts

- **NCT ID:** NCT06972602
- **Lead sponsor:** Eye & ENT Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06972602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06972602, "High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06972602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*